title: Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
authors.affiliation: Department of Preventive Medicine and USC/Norris Comprehensive Cancer Center and Hospital, University of Southern California Keck School of Medicine, Los Angeles, California 90089-9176, USA.
authors.forename: Celeste L
authors.initials: CL
authors.lastname: Pearce
authors.forename: Nick M
authors.initials: NM
authors.lastname: Makridakis
authors.forename: Ronald K
authors.initials: RK
authors.lastname: Ross
authors.forename: Malcolm C
authors.initials: MC
authors.lastname: Pike
authors.forename: Laurence N
authors.initials: LN
authors.lastname: Kolonel
authors.forename: Brian E
authors.initials: BE
authors.lastname: Henderson
authors.forename: Juergen K V
authors.initials: JK
authors.lastname: Reichardt
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics*; D019943:Amino Acid Substitution; D016022:Case-Control Studies; D005006:Ethnicity; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000209:etiology / Q000235:genetics*; D012042:Registries; D012307:Risk Factors
chemical_list: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase